These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Influence of glycemic control on the development of diabetic cardiovascular and kidney disease. Saha SA; Tuttle KR Cardiol Clin; 2010 Aug; 28(3):497-516. PubMed ID: 20621253 [TBL] [Abstract][Full Text] [Related]
37. [112th Scientific Meeting of the Japanese Society of Internal Medicine: Symposium: Emerging Comorbidities of Diabetes Mellitus: Drug Therapy of Diabetes Mellitus to Prevent Complications]. Inagaki N Nihon Naika Gakkai Zasshi; 2015 Sep; 104(9):1912-6. PubMed ID: 30160897 [No Abstract] [Full Text] [Related]
38. Cardiovascular Protection with Anti-hyperglycemic Agents. Deedwania P; Acharya T Am J Cardiovasc Drugs; 2019 Jun; 19(3):249-257. PubMed ID: 30767126 [TBL] [Abstract][Full Text] [Related]
39. The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials. Drexel H; Rosano GMC; Lewis BS; Huber K; Vonbank A; Dopheide JF; Mader A; Niessner A; Savarese G; Wassmann S; Agewall S Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):97-103. PubMed ID: 31298686 [TBL] [Abstract][Full Text] [Related]
40. Oral hypoglycaemic drugs and cardiovascular disease in maturity onset diabetes. Raheja BS Indian Heart J; 1979; 31(4):213-7. PubMed ID: 489037 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]